![]() Actual results may differ materially and adversely from current expectations based on a number of factors affecting Endo's businesses, including, among other things, the following: the outcome of our strategic review, contingency planning and any potential restructuring the timing, impact or results of any pending or future litigation, investigations, proceedings or claims, including opioid, tax and antitrust matters actual or contingent liabilities settlement discussions or negotiations the impact of competition including loss of exclusivity and generic competition our ability to satisfy judgments or settlements or to pursue appeals including bonding requirements our ability to adjust to changing market conditions our inability to maintain compliance with financial covenants and operating obligations which would expose us to potential events of default under our outstanding indebtedness our ability to incur additional debt or refinance our outstanding indebtedness a significant reduction in our short-term or long-term revenues which could cause us to be unable to fund our operations and liquidity needs the effectiveness of advertising and other promotional campaigns unfavorable publicity regarding the misuse of opioids and our ability to develop our product pipeline and to continue to develop the market for products. All forward-looking statements in this press release reflect Endo's current expectations of future events based on existing trends and information and represent Endo's judgment only as of the date of this press release. Statements including words or phrases such as "believe," "expect," "anticipate," "intend," "estimate," "plan," "will," "may," "look forward," "intend," "future," "potential" or similar expressions are forward-looking statements. Sims and any statements related to the expansion of Endo's product pipeline or the acquisition, timing, development, approval, launch or commercialization of any products. For additional information please visit Forward-Looking StatementsĬertain information in this press release may be considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and any applicable Canadian securities legislation including, but not limited to, the statements by Mr. The Company has active programs in critical patient care, acute pain management, long acting injectables, and hospital injectables. Nevakar Injectables is developing a broad portfolio of injectable products for use in the hospital and ambulatory care settings. is a wholly owned subsidiary of Nevakar, Inc., a fully integrated privately held, late-stage biopharmaceutical company with an extensive portfolio of products in the ophthalmic and injectable areas. Learn more at connect with us on LinkedIn. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Our decades of proven success come from passionate team members around the globe collaborating to bring the best treatments forward. This may reduce waste and costs, optimize convenience and workflow and reduce the chance for preparation error-all of which support quality patient care.Įndo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Ready-to-use, or RTU, products help streamline operations for hospitals by eliminating the need to prepare or transfer the product before patient administration. This acquisition is separate from Endo's previously announced exclusive licensing agreement with Nevakar. The one-time payment is expected to be expensed immediately in the second quarter as acquired in-process research and development costs. Under the terms of the agreement, EVL purchased the six product candidates from Nevakar Injectables for a one-time payment of $35 million. Endo's Par Sterile Products business will commercialize the products in the United States. With the acquisition, Endo controls all remaining development, approval, launch and commercialization activities for these product candidates. The product candidates are in various stages of development, with the first launch expected in 2025. "We look forward to further developing and bringing these durable and differentiated products to market-and to the healthcare providers and patients who need them." "These six product candidates that would be used in critical care settings meaningfully expand Endo's ready-to-use injectable product pipeline," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |